Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;39(1):69-78.
doi: 10.15605/jafes.039.01.03. Epub 2023 Oct 27.

Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management

Frederick Berro Rivera  1 , Bettina Therese Escolano  2 , Frances Micole Nifas  2 , Sarang Choi  2 , Genquen Philip Carado  3 , Edgar Lerma  4 , Krishnaswami Vijayaraghavan  5 , Marc Gregory Yu  6
Affiliations
Review

Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management

Frederick Berro Rivera et al. J ASEAN Fed Endocr Soc. 2024.

Abstract

Sarcopenia refers to an age-related reduction of lean body mass. It showed a reciprocal relationship with cardiovascular diseases. Thus, it is imperative to explore pathophysiological mechanisms explaining the relationship between sarcopenia and cardiovascular diseases, along with the clinical assessment, and associated management. In this review, we discuss how processes such as inflammation, oxidative stress, endothelial dysfunction, neural and hormonal modifications, as well as other metabolic disturbances influence sarcopenia as well as its association with cardiovascular diseases. Moreover, this review provides an overview of both non-pharmacological and pharmacological management for patients with sarcopenia and cardiovascular diseases, with a focus on the potential role of cardiovascular drugs to mitigate sarcopenia.

Keywords: aging; cardiovascular diseases; inflammation; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflict of interest.

Figures

Figure 1
Figure 1
Pathophysiology of Sarcopenia and CVD and their interaction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191): 2636–46. PMID: 31171417. 10.1016/S0140-6736(19)31138-9. - DOI - PubMed
    1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. . Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1): 16-31. PMID: 30312372. PMCID: . 10.1093/ageing/afy169. - DOI - PMC - PubMed
    1. Chen LK, Liu LK, Woo J, et al. . Sarcopenia in Asia: Consensus report of the Asian Working Group for sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101. PMID: 24461239. 10.1016/j.jamda.2013.11.025. - DOI - PubMed
    1. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: Facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129-33. PMID: 21475695. PMCID: . 10.1007/s13539-010-0014-2. - DOI - PMC - PubMed
    1. Tyrovolas S, Haro JM, Mariolis A, et al. . Skeletal muscle mass and body fat in relation to successful ageing of older adults: The multi-national MEDIS study. Archives of Gerontology and Geriatrics. 2016;66: 95–101. PMID: 27266673. 10.1016/j.archger.2016.04.017. - DOI - PubMed

LinkOut - more resources